Crossmark

Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA study

Crossref DOI link: https://doi.org/10.1186/s13722-024-00506-1

Published Online: 2024-10-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pinhal, Mélanie

Schreck, Benoit

Leboucher, Juliette

,

Abesdris, Julie

Barrangou-Pouyes-Darlas, Malcolm

Eyzop, Emeline

Galantai, Valentine

Kunze-, Lucie Robert

Lambert, Sylvain

Prétagut, Stéphane

Verholleman, Audrey

Victorri-Vigneau, Caroline

Laforgue, Edouard-Jules

Grall-Bronnec, Marie
License Information

Text and Data Mining valid from 2024-10-16

Version of Record valid from 2024-10-16
More Information

Article History

Received: 11 April 2024

Accepted: 23 September 2024

First Online: 16 October 2024

Declarations

:

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. The STIGMA study was approved by the local ethics committee (<i>Groupe Nantais d'Ethique dans le Domaine de la Santé</i>). The participants were informed about this study, and their written consent was systematically collected.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below